Hyperfine (HYPR) Cash & Equivalents Growth (3y) (2023 - 2026)
Hyperfine (HYPR) Cash & Equivalents Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.57 Bn | 193.97 Bn | 7.27 Bn | -13.31% |
| 2 | Stryker | 127.25 Bn | 123.77 Bn | 4.50 Bn | 34.27% |
| 3 | Medtronic | 118.81 Bn | 109.59 Bn | 6.41 Bn | 8.10% |
| 4 | Boston Scientific | 73.35 Bn | 72.81 Bn | 3.85 Bn | 8.16% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 40.74% |
| 6 | Dexcom | 34.28 Bn | 32.34 Bn | 830.00 Mn | -2.57% |
| 7 | GE HealthCare Technologies | 33.75 Bn | 31.64 Bn | 2.18 Bn | 2.72% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 38.28% |
| 9 | Steris | 23.03 Bn | 22.55 Bn | 684.20 Mn | 32.23% |
| 10 | Hyperfine | 88.55 Mn | 43.79 Mn | 1.98 Mn | -22.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.66% |
| Mar 31, 2026 | -26.81% |
| Dec 31, 2025 | -33.16% |
| Sep 30, 2025 | -45.40% |
| Jun 30, 2025 | -44.05% |
| Mar 31, 2025 | -41.05% |
| Dec 31, 2024 | -41.55% |
| Sep 30, 2024 | -11.25% |
| Jun 30, 2024 | -11.41% |
| Mar 31, 2024 | -9.84% |
| Dec 31, 2023 | 6.25% |